Wall Street turned cautious again this month as the immediate enthusiasm for AI faded. A renewed geopolitical flare-up between the U.S. and Iran, together with fresh inflation concerns ahead of upcoming CPI data, contributed to a defensive rotation across asset classes.
Institutional capital has notably moved toward the healthcare complex even as earlier strength in semiconductor infrastructure names dominated headlines. Hardware plays that led earlier gains - such as Marvell Technology (MRVL), which rose 21.62%, and Veeco (VECO), up 17.36% - have been joined by a wave of inflows into healthcare equities.
Subscribers to an AI-driven ProPicks strategy who received monthly selections at the start of the period were already positioned in several of the healthcare winners that have since posted substantial returns.
The following healthcare stocks recorded notable June performance, with some also showing large cumulative gains since they were first chosen by the ProPicks models:
- Haemonetics (HAE): +17.09% in June alone (+44.32% since chosen)
- Amneal Pharma A (AMRX): +13.88% in June alone
- Molina Healthcare (MOH): +10.81% in June alone (+49.51% since chosen)
- Cardinal Health (CAH): +8.98% in June alone (+36.33% since chosen)
- UnitedHealth (UNH): +8.72% in June alone (+27.78% since chosen)
Beyond these names, the ProPicks models point to multi-sector winners that continue to produce outsized total returns since their inclusion:
- Consensus Cloud Solutions (CCSI): +60.21% since chosen
- Nucor (NUE): +58.26% since chosen
- Texas Instruments (TXN): +36.08% since chosen
- Navigator Holdings (NVGS): +26.55% since chosen
- Centene (CNC): +24.13% since chosen
What the models flagged
ProPicks' data-driven strategies identified specific valuation and profitability characteristics that underpinned the healthcare selections before the broader market shifted into the sector.
Haemonetics (HAE) was highlighted by the models as a pronounced valuation disconnect relative to its operating performance. At the time it was selected, the stock had retreated to roughly 56% of its 52-week high while the company was delivering robust underlying results: year-over-year EBITDA growth of 23.6%, and an earnings beat where reported EPS was $1.10 against a $1.01 consensus. The business reported a 58.8% gross margin and the model noted a PEG ratio of 0.34, indicating the stock was an undervalued cash generator. A subsequent analyst upgrade to Buy with a $90 price target lent additional support to that investment thesis.
Amneal Pharmaceuticals (AMRX) was chosen for a different but equally compelling set of metrics. The models singled out accelerating profitability following a 65% earnings surprise in the most recent quarter and a 19% increase in adjusted Q1 EBITDA. Gross margins expanded by 500 basis points year-over-year. The company’s acquisition of Kashiv BioSciences was noted in the models as a strategic move that opens exposure to the sizable biosimilars opportunity. Despite an 80% run over the past year, the stock traded at an ultra-low PEG ratio of 0.04 at selection, while the models referenced management’s longer-term revenue trajectory toward a $4.5 billion target by 2030 as a driver of mispricing versus long-term upside.
Model process and portfolio construction
The ProPicks engine evaluates thousands of global equities each month using a blend of historical and forward-looking metrics. The system ingests more than 15 years of financial data across in excess of 150 quantitative models to surface up to 20 high-conviction names per strategy based on projected medium-term upside potential.
Strategies are rebalanced on a monthly cadence: new opportunities are added, high performers are retained, and names that no longer meet the criteria are removed. For performance transparency, each strategy applies equal weighting across selected stocks, though investors may choose custom allocations.
Since its official launch in November 2023, the ProPicks AI strategy has recorded a cumulative return of +207.04%, outperforming the S&P 500 by +132.90% over the same period. The figures cited reflect returns logged since the strategy’s launch date.
Positioning through cycles
The recent defensive rotation underscores the role of valuation and profitability screening in identifying assets that can re-rate when sentiment shifts. The ProPicks approach emphasizes holding high-conviction names through their full growth cycle so capital is positioned ahead of episodic flows into safer, defensive sectors such as healthcare.
Members who received the AI-powered picks at the start of the month were positioned to capture the June cross-sector gains at modest subscription pricing. The model-driven selections span hospital technologies, managed care, and global biopharmaceutical exposure, reflecting a focus on companies with improving underlying economics and identifiable valuation misalignments.
Subscription and transparency notes
Subscription prices mentioned at the time of publication are accurate to that moment and offers may vary over time and by region. The ProPicks documentation describes the selection methodology, monthly rebalancing, and the equal-weight portfolio framework used to measure strategy performance.
Investors interested in the full list of June picks and details on individual model signals are directed to the service’s member resources.